After Pfizer withdrew its sickle cell drug from the market, patients with the condition and their doctors were left ...
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. In a new ...
The CDC said an investigation into a human H5N1 bird flu infection in Missouri has found four additional health care workers ...
A dispute over a Duchenne gene therapy highlights thorny issues surrounding FDA approvals and insurance policies.
Dhillon is an instructor in the Division of Global Health Equity at Brigham and Women’s Hospital and Harvard Medical School.
Top of the morning to you, and a fine one it is, despite the gray skies hovering over the Pharmalot campus. We are doing our best to maintain sunny spirits, though, because once again, we recall ...
What comes next for Pfizer's Oxbryta sickle cell drug —Cassava Sciences' SEC charges —Bristol's new schizophrenia treatment ...
MedStar executive Raj Ratwani says the idea of shared responsibility should be central to how health AI is regulated.
Medicare’s controversial decision to condition coverage for even fully approved Alzheimer’s drugs is here to stay, per a top ...
Opinion: If Congress doesn’t finalize an extension for the Older Americans Act by the end of September, critical services ...
Pfizer is removing its Oxbryta pill for sickle cell disease from all markets globally due to safety risks, including deaths.
Cobenfy was approved to reduce the psychotic symptoms associated with schizophrenia. It is a new type of medicine that works ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback